Sarah Kremen, MD, director of the Neurobehavior Program in the Jona Goldrich Center for Alzheimer’s and Memory Disorders, Cedars-Sinai, Los Angeles.
Just two years after the aducanumab (Aduhelm) controversy, the U.S. Food and Drug Administration has approved another drug for Alzheimer’s…
Read More >
